58
Participants
Start Date
June 11, 2018
Primary Completion Date
August 30, 2023
Study Completion Date
August 30, 2023
durvalumab, tremelimumab, paclitaxel
Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
Asan Medical Center, Seoul
Lead Sponsor
Hallym University Medical Center
OTHER
Seoul National University Bundang Hospital
OTHER
Asan Medical Center
OTHER